RxDoctor Payments DataLook up a doctor →

John McConnell, MD

Pulmonary Disease · Louisville, KYNPI 1902831761

Payments from drug & device makers

$3,536,522in general payments, 2019–2025

Across 1,154 payments — averaging $3064.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$1.6M
  • Actelion Pharmaceuticals US, Inc.$625K
  • Janssen Research & Development, LLC$314K
  • Bayer$263K
  • Actelion Pharmaceuticals, Ltd$236K
  • United Therapeutics Corporation$202K
  • plus $306K from 24 others
$1,159in research payments, 2019–2025

Across 1 payment — averaging $1159.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • E.r. Squibb & Sons, L.L.C.$1K

What the payments were for

  • Consulting fees$125,25514%
  • Speaking & faculty fees$595,53169%
  • Travel & lodging$116,35013%
  • Food & beverage$27,1103%
  • Education$1980%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,536,522 in reported general payments places this provider in the 95th percentile of 226 pulmonary disease providers in Kentucky.

See all pulmonary disease providers in Kentucky

Medicare billing

Part B allowed, 2024
$278,706
Medicare patients
507
Services billed
2,583

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan946$11,971,909
UptraviSelexipag476$10,681,793
AdempasRiociguat610$8,612,895
WinrevairSotatercept-Csrk238$3,930,503
OfevNintedanib Esylate55$717,806
OpsynviMacitentan/Tadalafil41$525,341
Tyvaso DpiTreprostinil18$435,554
Ambrisentan114$288,070
Prolastin CAlpha-1-Proteinase Inhibitor23$202,547
LetairisAmbrisentan17$200,898
AdcircaTadalafil38$153,785
Orenitram ErTreprostinil Diolamine20$152,758
Trelegy ElliptaFluticasone/Umeclidin/Vilanter164$144,926
GlassiaAlpha-1-Proteinase Inhibitor13$73,306
RevatioSildenafil Citrate12$62,196

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi, Opsynvi$624,567$23,179,0441,463 claims
BayerAdempas$262,918$8,612,895610 claims
MerckWinrevair$1,590,923$3,930,503238 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$377$777,865141 claims
GSKTrelegy Ellipta, Breo Ellipta$272$203,208290 claims
Grifols USA, LLCProlastin C$14$202,54723 claims
United Therapeutics CorporationAdcirca$201,578$153,78538 claims
AstraZenecaBreztri Aerosphere, Symbicort$350$84,392144 claims
Johnson & JohnsonVeletri$9,274$36,71512 claims
PfizerEliquis$32,074$36,32751 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 226 pulmonary disease providers in Kentucky.

Other pulmonary disease in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →